Clinical trials are studies designed to find new and better ways to treat patients with cancer. Through clinical trials, scientists and physicians at the University of Maryland Marlene and Stewart Greenebaum Cancer Center are breaking new ground in the development of cancer treatments. Access to clinical trials is an important advantage of receiving your radiation therapy at UM BWMC.

We offer patients access to some of the 125 clinical trials currently being conducted at UMGCC. In this way, our patients may be eligible for new treatments not yet commercially available elsewhere. If you may be eligible for participation in one of the trials that are currently available, your physician may discuss it with you at the time of your consultation. If you are interested in one of the trials that are available in our department after discussing it with your physician, a research associate assists in coordinating participation.

Clinical Trials Currently Available at UM BWMC:


  • GCC 1547 - Ultrasound-based bladder scanning for reproducibility of bladder-filling during abdominopelvic external beam radiotherapy
  • A031803 – "Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer"


  • RTOG 3510 - Pragmatic Phase II Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
  • GCC 18124 - Phase II Multi-center Trial Evaluating 5 Fraction S-PBI (Stereotactic Partial Breast Irradiation) for Early Stage Breast Cancer Using the GammaPod
  • GCC 1876: Tumor Bed Dose Delivery using a Breast Specific Radiosurgery Device, The GammaPod: Registry Study and Evaluation of Quality of Life with Development of Sizing Nomogram
  • A191901 – "Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions"
  • EA1151 – "Tomosynthesis Mammographic Imaging Screening Trial"


  • A021502 - Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair.


  • GCC 1122 - "Observational study of hepatic metastasis of colorectal origin. International survey METSURVEY." This study is offered by the Medical Director of the Tate Cancer Center, Cherif Boutros, MD, MSc, FACS.


  • GCC 1301 - "Postoperative heme oxygenase induction and carbon monoxide production as a novel method to assess hepatic regeneration and predict hepatic related morbidity after partial hepatectomy." This study is offered by the Medical Director of the Tate Cancer Center, Cherif Boutros, MD, MSc, FACS.


  • A151216 - "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) A screening trial for A081105, E4512 and EA5142"
  • E4512 - "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein"
  • NRG-CC003 - A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer.
  • A081801 – "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)"


  • NCT Clinical Trial 02041936 - "Outcomes of ablation of unresectable pancreatic cancer using the NanoKnife Irreversible Electroporation (IRE) System." This study is offered by the Medical Director of the Tate Cancer Center, Cherif Boutros, MD.
  • HP 00067132 - "Assessing the significance of Platelet to Lymphocyte Ratio (PLR) as a simple, non-invasive marker of immunological response in pancreatic cancer and its association with tumor infiltrated T cells." This study is offered by the Medical Director of the Tate Cancer Center, Cherif Boutros, MD.
  • EA2185 – "Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs"


  • NRG-GU002 - Phase II-III Trial Of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or without Adjuvant Docetaxel.
  • NRG-GU005 - Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer.
  • NRG-GU006 - A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer.
  • NRG-GU007 - Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I).
  • GCC 1738 - PARTIQoL (Prostate Advanced Radiation Technologies Investigating Quality of Life) A Companion to Phase III Randomized PARTIQoL Clinical Trial.
  • GCC 1940 - A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE).